| Name | Belumosudil mesylate |
| Description | Belumosudil mesylate (KD025 mesylate) is a selective and highly efficient ROCK2 inhibitor with antifibrotic activity. It inhibits ROCK1 and can be used in chronic graft-versus-host disease research. |
| In vitro | Belumosudil mesylate is a selective inhibitor of ROCK2, with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively.[1]
40 μM Belumosudil mesylate significantly down-regulated the levels of Tsp-1 and CTGF mRNA in pulmonary artery smooth muscle cells (PASMC). [1] |
| In vivo | Intraperitoneal injection of 100, 200, or 300 mg/kg Belumosudil mesylate dose-dependently reduced infarct volume after transient middle cerebral artery occlusion. Belumosudil mesylate was at least as effective in aged, diabetic, or female mice as in normal adult male mice. [2] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 1 mg/mL (1.82 mM), Sonication and heating are recommended.
DMSO : 20 mg/mL (36.46 mM), Sonication and heating are recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.82 mM), Sonication is recommended.
|
| Keywords | SLx-2119mesylate | KD-025 Mesylate |
| Inhibitors Related | ITX3 | Fasudil | GSK180736A | SAR407899 hydrochloride | RKI-1447 | Fasudil hydrochloride | Y-27632 dihydrochloride | Tofacitinib | Y-27632 | ROCK-IN-5 | Thiazovivin | CAY10746 |
| Related Compound Libraries | Bioactive Compound Library | Drug-induced Liver Injury (DILI) Compound Library | ReFRAME Related Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Stem Cell Differentiation Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library | Anti-Cancer Drug Library |
United States
